Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds

Merck gains rights to LaNova’s PD-1/VEGF bispecific antibody in deal worth over $3.2bn

Merck gains rights to LaNova’s PD-1/VEGF bispecific antibody in deal worth over $3.2bn